MCID: ACT020
MIFTS: 52

Acute T Cell Leukemia

Categories: Cancer diseases, Immune diseases, Blood diseases, Rare diseases, Skin diseases

Aliases & Classifications for Acute T Cell Leukemia

MalaCards integrated aliases for Acute T Cell Leukemia:

Name: Acute T Cell Leukemia 12 15
T-Cell Acute Lymphoblastic Leukemia 12 29 6
Leukemia, Acute T-Cell 13 40
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 73
Precursor T-Cell Lymphoblastic Lymphoma 73
Precursor T Lymphoblastic Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5603
ICD10 33 C91.5 C91.50
MeSH 44 D015459
NCIt 50 C3184

Summaries for Acute T Cell Leukemia

MalaCards based summary : Acute T Cell Leukemia, also known as t-cell acute lymphoblastic leukemia, is related to precursor t-cell acute lymphoblastic leukemia and myeloma, multiple. An important gene associated with Acute T Cell Leukemia is BCL10 (B Cell CLL/Lymphoma 10), and among its related pathways/superpathways are PAK Pathway and PI3K-Akt signaling pathway. The drugs Arranon and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include t cells, thyroid and b cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Acute T Cell Leukemia

Graphical network of the top 20 diseases related to Acute T Cell Leukemia:



Diseases related to Acute T Cell Leukemia

Symptoms & Phenotypes for Acute T Cell Leukemia

GenomeRNAi Phenotypes related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

26 (show all 30)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.04 LMO1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.04 CD151 MTOR
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.04 MTOR LPP
4 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.04 HSD17B1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.04 LPP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.04 PTEN
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.04 PTEN
8 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.04 MTOR PTEN
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.04 HSD17B1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.04 HSD17B1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.04 PTEN
12 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.04 LPP
13 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.04 CD151
14 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.04 HSD17B1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.04 PTEN
16 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.04 CD151
17 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.04 LPP
18 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.04 CD151
19 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.04 MTOR LMO1 PTEN CD151
20 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.04 LMO1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.04 LPP
22 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.04 LMO1 PTEN
23 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.04 MTOR HSD17B1 LMO1 LPP
24 Increased shRNA abundance (Z-score > 2) GR00366-A-76 10.04 LPP
25 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.04 LMO1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.04 CD151
27 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.04 MTOR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.04 LPP
29 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.04 PTEN
30 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.04 LPP

MGI Mouse Phenotypes related to Acute T Cell Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.02 CXCL12 BAX FASLG LPP BCL10 MTOR
2 endocrine/exocrine gland MP:0005379 9.92 BAX FASLG BCL10 HSD17B1 MTOR CASP8
3 hematopoietic system MP:0005397 9.91 BAX FASLG BCL10 MTOR CASP8 CD151
4 immune system MP:0005387 9.81 BAX FASLG BCL10 MTOR CASP8 CD151
5 mortality/aging MP:0010768 9.65 CXCL12 BAX FASLG LMO1 LPP BCL10
6 renal/urinary system MP:0005367 9.1 BAX FASLG MTOR CASP8 CD151 PTEN

Drugs & Therapeutics for Acute T Cell Leukemia

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005

Drugs for Acute T Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 213)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bupivacaine Approved, Investigational Phase 4,Phase 1,Phase 2 2180-92-9, 38396-39-3 2474
2
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
3
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
4
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
5 Adrenergic Agents Phase 4,Phase 2
6 Neurotransmitter Agents Phase 4,Phase 2
7 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Respiratory System Agents Phase 4
10 Central Nervous System Depressants Phase 4,Phase 1,Phase 2
11 Adrenergic Agonists Phase 4
12 Adrenergic alpha-Agonists Phase 4
13 Adrenergic beta-Agonists Phase 4
14 Mydriatics Phase 4
15 Anesthetics Phase 4,Phase 1,Phase 2
16 Anesthetics, Local Phase 4,Phase 1,Phase 2
17 Vasoconstrictor Agents Phase 4
18 Anti-Asthmatic Agents Phase 4
19 Epinephryl borate Phase 4,Not Applicable
20 Bronchodilator Agents Phase 4
21 Calamus Nutraceutical Phase 4
22
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
23
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
24
Fludarabine Approved Phase 3,Phase 1 21679-14-1, 75607-67-9 30751
25
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
26
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
27
Dasatinib Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 302962-49-8 3062316
28
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754
29
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
30
Ifosfamide Approved Phase 3 3778-73-2 3690
31
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1 3375-50-6 598
32
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
33
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
34
Cortisone acetate Approved, Investigational Phase 3,Phase 2 1950-04-4, 50-04-4 5745
35
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
36
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
37
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
38
Bortezomib Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 179324-69-7 387447 93860
39
Daunorubicin Approved Phase 3,Phase 2,Not Applicable 20830-81-3 30323
40
Thioguanine Approved Phase 3,Phase 2 154-42-7 2723601
41
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
42
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
43
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
44
Pegaspargase Approved, Investigational Phase 3,Phase 2,Phase 1 130167-69-0
45
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
46
Amsacrine Approved, Investigational Phase 2, Phase 3 51264-14-3 2179
47
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 3 123318-82-1 119182
48
Idarubicin Approved Phase 3,Phase 2,Not Applicable 58957-92-9 42890
49
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-24-8 5755
50
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 83-43-2 6741

Interventional clinical trials:

(show top 50) (show all 109)
# Name Status NCT ID Phase Drugs
1 Neurotoxicity of Spinal Anesthesia With Ropivacaine and Bupivacaine Recruiting NCT03293472 Phase 4 Ropivacaine;Bupivacaine
2 Postoperative Analgesia After Elective Hip Surgery - Effect of Obturator Nerve Blockade Recruiting NCT03064165 Phase 4 Bupivacaine-epinephrine;Sodium Chloride 9mg/mL
3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed NCT00408005 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
4 Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
5 Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
6 Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III Completed NCT00483132 Phase 3 interferon alpha 2a
7 ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy Completed NCT00816049 Phase 3 6MPindividualized;6MPfixed
8 Stopping Postpartum Vitamin A Supplementation: Missing Concealed Benefit Completed NCT02043223 Phase 2, Phase 3
9 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia Completed NCT00613457 Phase 3 dexamethasone;asparaginase;Asparaginase;cyclophosphamide;cytarabine;daunorubicin;doxorubicin;Etoposide;Ifosfamide;mercaptopurine;Methotrexate;prednisone;thioguanine;Vincristine;Vindesine
10 Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment Recruiting NCT02881086 Phase 3 Rituximab;Nelarabine;PEG-Asparaginase;Imatinib;Idarubicin;Dexamethasone;Cyclophosphamide;Fludarabine;Vincristine;Mercaptopurine;VP16;Daunorubicin (DNR);Methotrexate;Cytarabine;Vindesine;Adriamycin;Prednisolone
11 Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL Recruiting NCT01228331 Phase 2, Phase 3 Amsacrine;Clofarabine;Cyclophosphamide;Cytarabine;Daunorubicin hydrochloride;Dexamethasone;Doxorubicin hydrochloride;Etoposide phosphate;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Thioguanine;Vincristine sulfate
12 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Recruiting NCT03117751 Phase 2, Phase 3 Prednisone;Vincristine;Daunorubicin;Pegaspargase;Erwinase®;Rituximab;Cyclophosphamide;Cytarabine;Mercaptopurine;Dasatinib;Methotrexate;Blinatumomab;Ruxolitinib;Bortezomib;Dexamethasone;Doxorubicin;Etoposide;Clofarabine;Vorinostat;Idarubicin;Nelarabine
13 A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Recruiting NCT02716233 Phase 3 pegaspargase 1250 IU/m2 x 2;pegaspargase 2500 IU/m2 x 1
14 Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
15 Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Recruiting NCT03007147 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Dexrazoxane Hydrochloride;Doxorubicin;Etoposide;Ifosfamide;Imatinib Mesylate;Leucovorin Calcium;Mercaptopurine;Mercaptopurine;Mesna;Methotrexate;Methylprednisolone;Pegaspargase;Prednisolone;Therapeutic Hydrocortisone;Thioguanine;Vincristine Sulfate
16 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Recruiting NCT03020030 Phase 3 Pegaspargase;Erwinia asparaginase;Cyclophosphamide;CYTARABINE;DASATINIB;DEXAMETHASONE;Dexrazoxane;Doxorubicin;ETOPOSIDE;HYDROCORTISONE;LEUCOVORIN CALCIUM;MERCAPTOPURINE;METHOTREXATE;NELARABINE;Vincristine
17 International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia Active, not recruiting NCT01117441 Phase 3 PEG-L-asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine;daunoxome;fludarabine
18 Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Suspended NCT02112916 Phase 3 Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
19 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL) Completed NCT00684619 Phase 2 Nelarabine
20 A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL Completed NCT02518113 Phase 1, Phase 2 LY3039478;Dexamethasone;Placebo
21 Treatment of Relapsed T-Cell Acute Lymphoblastic Leukemia or T-Lymphoblastic Lymphoma With MabCampath Completed NCT00199030 Phase 2 Alemtuzumab (MabCampath);Cladribine
22 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma Completed NCT00061048 Phase 2
23 Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052) Completed NCT00687323 Phase 2 temozolomide
24 Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia Completed NCT00095381 Phase 2 forodesine hydrochloride (BCX-1777)
25 Losartan Versus Atenolol for the Treatment of Marfan Syndrome Completed NCT00593710 Phase 2 Losartan;Atenolol
26 506U78 in Treating Patients With Refractory Hematologic Cancer Completed NCT00002970 Phase 2 nelarabine;methotrexate;cytarabine;therapeutic hydrocortisone
27 Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
28 Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed NCT00873093 Phase 2 L-asparaginase;doxorubicin hydrochloride;therapeutic hydrocortisone;vincristine sulfate;cytarabine;prednisone;bortezomib;pegaspargase;methotrexate;etoposide phosphate;cyclophosphamide;leucovorin calcium;High Dose MTX
29 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed NCT01811212 Phase 2 Cabozantinib S-malate
30 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2 Bortezomib
31 A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leuk Recruiting NCT03384654 Phase 2 Daratumumab;Vincristine;Prednisone;Doxorubicin;Cyclophosphamide;Cytarabine;6-mercaptopurine;Methotrexate
32 BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma Recruiting NCT02763384 Phase 2 BL-8040;Nelarabine
33 Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma Recruiting NCT00501826 Phase 2 Doxorubicin;Cyclophosphamide;Cytarabine;Dexamethasone;Methotrexate;Vincristine;Nelarabine;Mesna;6-MP;Prednisone
34 Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia Recruiting NCT02767934 Phase 2
35 Dose-finding Study of Intrathecal Paracetamol Administered Immediately Before Spinal Anaesthesia Recruiting NCT02654860 Phase 1, Phase 2 Paracetamol 3%;Placebo injection containing Saline solution 0.9%;Hyperbaric Bupivacaine HCl 0.5%
36 Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia Recruiting NCT03504644 Phase 1, Phase 2 Venetoclax;Vincristine Liposomal
37 Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia Recruiting NCT02484430 Phase 2 Sapanisertib
38 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Recruiting NCT02742727 Phase 1, Phase 2
39 Lenvatinib and Pembrolizumab in DTC Recruiting NCT02973997 Phase 2 Lenvatinib
40 Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma Active, not recruiting NCT00866749 Phase 2 Daunorubicin;Vincristine;PEG-asparaginase;Intrathecal Methotrexate;Cyclophosphamide;Cytarabine;Mercaptopurine;Methotrexate;Doxorubicin;Thioguanine
41 Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia Active, not recruiting NCT00792948 Phase 2 Cyclophosphamide;Cytarabine;Dasatinib;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Leucovorin Calcium;Methotrexate;Methylprednisolone;Prednisone;Sirolimus;Tacrolimus;Vincristine Sulfate
42 SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma Active, not recruiting NCT01574274 Phase 2 SC-PEG;Oncaspar
43 Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia Not yet recruiting NCT03575325 Phase 2 CPX-351
44 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL) Not yet recruiting NCT03207542 Phase 2 Daratumumab
45 Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Not yet recruiting NCT02538926 Phase 2 Asparaginase;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Imatinib Mesylate;Prednisone;Vincristine Sulfate
46 TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients Terminated NCT00415909 Phase 2 Imatinib Mesylate (IM);TALL-104 cells
47 Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL Terminated NCT00981799 Phase 1, Phase 2 Nelarabine;Etoposide;Cyclophosphamide;Methotrexate;Filgrastim
48 Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia Terminated NCT02999633 Phase 2 Isatuximab SAR650984;dexamethasone;dexamethasone;acetaminophen;ranitidine;diphenhydramine
49 Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Terminated NCT02518750 Phase 2 Dexamethasone;Panobinostat;Liposomal vincristine;Mitoxantrone;Peg-asparaginase;Bortezomib;Intrathecal Triples;High-dose methotrexate;6-Mercaptopurine;High-dose cytarabine;Nelarabine;Cyclophosphamide;Etoposide;Clofarabine
50 Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens Terminated NCT00419081 Phase 2 Forodesine Hydrochloride Sterile Solution, 5 mg/mL;Forodesine Hydrochloride Capsules (100 mg)

Search NIH Clinical Center for Acute T Cell Leukemia

Genetic Tests for Acute T Cell Leukemia

Genetic tests related to Acute T Cell Leukemia:

# Genetic test Affiliating Genes
1 T-Cell Acute Lymphoblastic Leukemia 29

Anatomical Context for Acute T Cell Leukemia

MalaCards organs/tissues related to Acute T Cell Leukemia:

41
T Cells, Thyroid, B Cells, Bone, Myeloid, Bone Marrow, Spinal Cord

Publications for Acute T Cell Leukemia

Articles related to Acute T Cell Leukemia:

(show top 50) (show all 438)
# Title Authors Year
1
Erratum: Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia [Corrigendum]. ( 29443320 )
2018
2
Study of NOTCH1 and FBXW7 Mutations and Its Prognostic Significance in South Indian T-Cell Acute Lymphoblastic Leukemia. ( 29200162 )
2018
3
Hepatic leukemia-associated macrophages exhibit a pro-inflammatory phenotype in Notch1-induced acute T cell leukemia. ( 29030004 )
2018
4
Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels. ( 29278703 )
2018
5
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. ( 29047158 )
2018
6
Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. ( 29949919 )
2018
7
A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing. ( 29954933 )
2018
8
Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia. ( 29948644 )
2018
9
In vitro combinatorial anti-proliferative and immunosuppressive effects of Brucea javanica extract with CX-4945 and imatinib in human T-cell acute lymphoblastic leukemia cells. ( 29966986 )
2018
10
MicroRNA expression and activity in T-cell acute lymphoblastic leukemia. ( 29435192 )
2018
11
<i>WT1</i> loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia. ( 29170254 )
2018
12
Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway. ( 27872496 )
2017
13
JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. ( 28484265 )
2017
14
Severe Mucha-Habermann-Like Ulceronecrotic Skin Disease in T-Cell Acute Lymphoblastic Leukemia Responsive to Basiliximab and Stem Cell Transplant. ( 28884915 )
2017
15
Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. ( 28671687 )
2017
16
Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD. ( 28280276 )
2017
17
MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy. ( 28482719 )
2017
18
Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. ( 28270453 )
2017
19
Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. ( 28074072 )
2017
20
The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia. ( 29023469 )
2017
21
RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia. ( 28790107 )
2017
22
NHE1 has a notable role in metastasis and drug resistance of T-cell acute lymphoblastic leukemia. ( 28943936 )
2017
23
T-cell acute lymphoblastic leukemia in infants has distinct genetic and epigenetic features compared to childhood cases. ( 27717083 )
2017
24
Impact of Aberrant Myeloid Antigen Expression on Outcomes of Patients with T-cell Acute Lymphoblastic Leukemia. ( 28584598 )
2017
25
The Relationship Between MMP-2 -1306C&amp;gt;T and MMP-9 -1562C&amp;gt;T Polymorphisms and the Risk and Prognosis of T-Cell Acute Lymphoblastic Leukemia in a Chinese Population: A Case-Control Study. ( 28719899 )
2017
26
New diagnosis of atypical ataxia-telangiectasia in a 17-year-old boy with T-cell acute lymphoblastic leukemia and a novel ATM mutation. ( 28123174 )
2017
27
The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL). ( 28159681 )
2017
28
Oncogenic ZEB2 activation drives sensitivity towards KDM1A inhibition in T-cell acute lymphoblastic leukemia. ( 28069602 )
2017
29
TFDP3 confers chemoresistance in minimal residual disease within childhood T-cell acute lymphoblastic leukemia. ( 27902457 )
2017
30
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. ( 28151717 )
2017
31
Epigenetic targeting of Notch1 driven transcription using the HDACi panobinostat is a potential therapy against T cell acute lymphoblastic leukemia. ( 28914259 )
2017
32
A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia. ( 29136506 )
2017
33
CD3D and PRKCQ work together to discriminate between B-cell and T-cell acute lymphoblastic leukemia. ( 27494091 )
2016
34
MiR-146b negatively regulates migration and delays progression of T-cell acute lymphoblastic leukemia. ( 27550837 )
2016
35
Clinicopathologic Effect of DNMT3A Mutation in Adult T-Cell Acute Lymphoblastic Leukemia. ( 26711182 )
2016
36
Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial. ( 26220040 )
2016
37
TRIB2 reinforces the oncogenic transcriptional program controlled by the TAL1 complex in T-cell acute lymphoblastic leukemia. ( 26202930 )
2016
38
MicroRNA-101 regulates T-cell acute lymphoblastic leukemia progression and chemotherapeutic sensitivity by targeting Notch1. ( 27666896 )
2016
39
Articulatin-D induces apoptosis via activation of caspase-8 in acute T-cell leukemia cell line. ( 27868169 )
2016
40
Complexity of NOTCH1 juxtamembrane insertion mutations in T-cell acute lymphoblastic leukemia. ( 26292904 )
2016
41
Increased PKCI+ activity by Rack1 overexpression is responsible for chemotherapy resistance in T-cell acute lymphoblastic leukemia-derived cell line. ( 27644318 )
2016
42
An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. ( 26944475 )
2016
43
Optimal interleukin-7 receptor-mediated signaling, cell cycle progression and viability of T-cell acute lymphoblastic leukemia cells rely on casein kinase 2 activity. ( 27470599 )
2016
44
miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20. ( 27637078 )
2016
45
Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement. ( 27756877 )
2016
46
Role of WW Domain-containing Oxidoreductase WWOX in Driving T Cell Acute Lymphoblastic Leukemia Maturation. ( 27339895 )
2016
47
Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors. ( 27694322 )
2016
48
Speed of leukemia development and genetic diversity in xenograft models of T cell acute lymphoblastic leukemia. ( 27191650 )
2016
49
Interleukin-15 deficiency promotes the development of T-cell acute lymphoblastic leukemia in non-obese diabetes mice with severe combined immunodeficiency. ( 26876593 )
2016
50
CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. ( 27449287 )
2016

Variations for Acute T Cell Leukemia

ClinVar genetic disease variations for Acute T Cell Leukemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 BCL10 NM_003921.4(BCL10): c.136_137insA (p.Ile46Asnfs) insertion Pathogenic rs387906351 GRCh37 Chromosome 1, 85736511: 85736511
2 BCL10 NM_003921.4(BCL10): c.136_137insA (p.Ile46Asnfs) insertion Pathogenic rs387906351 GRCh38 Chromosome 1, 85270828: 85270828
3 BAX NM_138761.3(BAX): c.199G> A (p.Gly67Arg) single nucleotide variant Pathogenic rs398122513 GRCh37 Chromosome 19, 49459056: 49459056
4 BAX NM_138761.3(BAX): c.199G> A (p.Gly67Arg) single nucleotide variant Pathogenic rs398122513 GRCh38 Chromosome 19, 48955799: 48955799
5 BAX NM_138761.3(BAX): c.115_121delGGGGGGG (p.Gly39Argfs) deletion Pathogenic rs398122842 GRCh37 Chromosome 19, 49458972: 49458978
6 BAX NM_138761.3(BAX): c.115_121delGGGGGGG (p.Gly39Argfs) deletion Pathogenic rs398122842 GRCh38 Chromosome 19, 48955715: 48955721

Copy number variations for Acute T Cell Leukemia from CNVD:

7 (show top 50) (show all 91)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21835 1 16200000 23900000 Copy number CHD5 T-cell acute lymphoblastic leukemia
2 21836 1 16200000 23900000 Copy number HES2 T-cell acute lymphoblastic leukemia
3 21837 1 16200000 23900000 Copy number HES3 T-cell acute lymphoblastic leukemia
4 32217 1 34600000 44100000 Copy number T-cell acute lymphoblastic leukemia
5 34248 1 5400000 7200000 Deletion T-cell acute lymphoblastic leukemia
6 38166 10 1 3800000 Copy number T-cell acute lymphoblastic leukemia
7 41844 10 24600000 31300000 Copy number ADARB2 T-cell acute lymphoblastic leukemia
8 41845 10 24600000 31300000 Copy number PFKP T-cell acute lymphoblastic leukemia
9 41846 10 24600000 31300000 Copy number PITRM1 T-cell acute lymphoblastic leukemia
10 41847 10 24600000 31300000 Copy number WDR37 T-cell acute lymphoblastic leukemia
11 46873 10 87900000 92900000 Loss PTEN T-cell acute lymphoblastic leukemia
12 48336 11 1 2800000 Gain IGF2 T-cell acute lymphoblastic leukemia
13 48337 11 1 2800000 Gain hsa-mir-675 T-cell acute lymphoblastic leukemia
14 48490 11 1 52900000 Duplication T-cell acute lymphoblastic leukemia
15 53563 11 31000000 36400000 Copy number WT1 T-cell acute lymphoblastic leukemia
16 57103 11 63100000 67100000 Gain MAP4K2 T-cell acute lymphoblastic leukemia
17 57104 11 63100000 67100000 Gain RASGRP2 T-cell acute lymphoblastic leukemia
18 60336 11 85300000 87900000 Loss PICALM T-cell acute lymphoblastic leukemia
19 60878 11 92800000 110400000 Copy number ATM T-cell acute lymphoblastic leukemia
20 61471 12 1 14800000 Deletion T-cell acute lymphoblastic leukemia
21 61531 12 1 35400000 Duplication T-cell acute lymphoblastic leukemia
22 61611 12 10000000 12600000 Loss CDKN1B T-cell acute lymphoblastic leukemia
23 61613 12 10000000 12600000 Loss hsa-mir-614 T-cell acute lymphoblastic leukemia
24 61779 12 10100000 14800000 Copy number CDKN1B T-cell acute lymphoblastic leukemia
25 74382 13 105800000 109100000 Gain TNFSF13B T-cell acute lymphoblastic leukemia
26 78375 13 50900000 55300000 Deletion DLEU7 T-cell acute lymphoblastic leukemia
27 78376 13 50900000 55300000 Deletion KCNRG T-cell acute lymphoblastic leukemia
28 82826 14 15600000 23600000 Deletion T-cell acute lymphoblastic leukemia
29 88309 6 135544145 135582003 Copy number MYB T-cell acute lymphoblastic leukemia
30 104069 16 66700000 70800000 Deletion CTCF T-cell acute lymphoblastic leukemia
31 108732 17 22200000 28800000 Duplication T-cell acute lymphoblastic leukemia
32 109390 17 25800000 31800000 Copy number NF1 T-cell acute lymphoblastic leukemia
33 109749 17 28800000 35400000 Deletion T-cell acute lymphoblastic leukemia
34 111430 17 3600000 6800000 Loss NALP1 T-cell acute lymphoblastic leukemia
35 115247 17 55600000 58400000 Gain MSI2 T-cell acute lymphoblastic leukemia
36 115248 17 55600000 58400000 Gain VEZF1 T-cell acute lymphoblastic leukemia
37 115617 17 58400000 59900000 Gain MAP3K3 T-cell acute lymphoblastic leukemia
38 115618 17 58400000 59900000 Gain SMURF2 T-cell acute lymphoblastic leukemia
39 115619 17 58400000 59900000 Gain hsa-mir-633 T-cell acute lymphoblastic leukemia
40 115878 17 59900000 64600000 Gain PRKCA T-cell acute lymphoblastic leukemia
41 116600 17 68400000 72200000 Gain GPR142 T-cell acute lymphoblastic leukemia
42 116601 17 68400000 72200000 Gain GPRC5C T-cell acute lymphoblastic leukemia
43 121278 18 41800000 46400000 Loss SMAD4 T-cell acute lymphoblastic leukemia
44 124174 19 1 6900000 Gain MKNK2 T-cell acute lymphoblastic leukemia
45 131214 19 53800000 57600000 Gain FUT2 T-cell acute lymphoblastic leukemia
46 131215 19 53800000 57600000 Gain RASIP1 T-cell acute lymphoblastic leukemia
47 133723 19 6900000 12600000 Gain INSR T-cell acute lymphoblastic leukemia
48 133733 19 6900000 13900000 Deletion T-cell acute lymphoblastic leukemia
49 140125 2 19200000 27900000 Copy number NCOA1 T-cell acute lymphoblastic leukemia
50 140126 2 19200000 27900000 Copy number TP53I3 T-cell acute lymphoblastic leukemia

Expression for Acute T Cell Leukemia

Search GEO for disease gene expression data for Acute T Cell Leukemia.

Pathways for Acute T Cell Leukemia

Pathways related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 BAX CASP8 CXCL12 FASLG MYH8 PTEN
2
Show member pathways
12.72 BAX CASP8 FASLG MTOR PTEN
3
Show member pathways
12.62 BCL10 CASP8 CXCL12 FASLG TRB
4
Show member pathways
12.49 BAX FASLG MTOR PTEN
5
Show member pathways
12.07 BAX CASP8 FASLG MTOR PTEN
6
Show member pathways
11.98 BAX CASP8 FASLG
7
Show member pathways
11.98 BAX CASP8 FASLG
8
Show member pathways
11.98 BAX CASP8 FASLG PTEN
9 11.94 BAX BCL10 CASP8 FASLG
10 11.82 BAX CASP8 CXCL12 FASLG MTOR PTEN
11 11.77 BAX FASLG PTEN
12
Show member pathways
11.75 FASLG MTOR TRB
13 11.75 BAX CASP8 MTOR PTEN
14
Show member pathways
11.56 BAX CASP8 FASLG
15 11.47 BAX CASP8 FASLG
16
Show member pathways
11.36 BAX FASLG MTOR PTEN
17 11.16 BAX CASP8 PTEN

GO Terms for Acute T Cell Leukemia

Biological processes related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.88 BAX BCL10 CASP8 FASLG PTEN
2 positive regulation of apoptotic process GO:0043065 9.8 BAX BCL10 FASLG PTEN
3 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.71 BCL10 CASP8 FASLG
4 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.63 BAX CASP8 FASLG
5 apoptotic signaling pathway GO:0097190 9.58 BAX CASP8 FASLG
6 cardiac muscle tissue development GO:0048738 9.52 MTOR PTEN
7 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.51 CASP8 FASLG
8 negative regulation of cell size GO:0045792 9.43 MTOR PTEN
9 extrinsic apoptotic signaling pathway GO:0097191 9.43 BAX CASP8 FASLG
10 B cell apoptotic process GO:0001783 9.37 BAX BCL10
11 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.33 BAX CASP8 FASLG
12 T cell apoptotic process GO:0070231 9.32 BCL10 FASLG
13 retinal cell programmed cell death GO:0046666 8.96 BAX FASLG
14 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 8.8 BAX CASP8 FASLG

Molecular functions related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 death receptor binding GO:0005123 8.62 CASP8 FASLG

Sources for Acute T Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....